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Abstract
Introduction: Acute kidney injury (AKI) increases mortality and morbidity of critically ill patients. Mortality of
patients treated with renal replacement therapy (RRT) is high. We aimed to evaluate the nationwide incidence of
RRT-treated AKI in Finland, hospital and six-month mortality, and health-related quality of life (HRQoL) of these
patients.
Methods: We performed a retrospective cohort study including all general intensive care unit (ICU) admissions in
Finland in 2007 through 2008. We identified patients who had received RRT due to AKI (RRT patients) and
compared these patients to ICU patients who were not treated with RRT (non-RRT patients). The HRQoL was
assessed by the EQ-5D index and visual analogue scale (VAS).
Results: We analysed the final cohort of 24,904 patients, of whom 1,686 received RRT due to AKI. The incidence of
RRT-treated AKI was 6.8% (95% confidence interval (CI) 6.5 to 7.1%) among ≥ 15-year-old general ICU patients,
which corresponds to a yearly population-based incidence of 19.2 per 100,000 (95% CI 17.9 to 20.5/100,000).
According to RIFLE (Risk, Injury, Failure) classification 26.6% (95% CI 26.0 to 27.2%) of patients had AKI (RIFLE R-F).
Hospital and six-month mortality of RRT patients were 35.0% and 49.4%. At six-months, RRT patients perceived their
health as good as non-RRT patients by VAS.
Conclusions: The population-based incidence of AKI treated with RRT was 19.2 per 100,000 in Finland and 6.8% of
all general ICU patients. The hospital and six-month mortality rates were lower than previously reported for ICU-
treated RRT patients.
Introduction
Acute kidney injury (AKI) increases mortality, length of
stay (LOS) and resource need in intensive care unit
(ICU) patients. The incidence of AKI has been reported
to vary between 6 and 70% among ICU patients depend-
ing on the definition [1-3]. The RIFLE (Risk, Injury, Fail-
ure) -classification for AKI based on serum creatinine
concentration and urine output was published in 2004
[4]. Patients receiving renal replacement therapy (RRT)
represent the most severe form of AKI.
The incidence of RRT-treated AKI in populations has
been reported to vary between 8 and 30 per 100,000/
year [5-12] with an increasing trend [11,12]. The inci-
dence of RRT-treated AKI among general ICU patients
lies between 4 and 8% [1,3,13,14]. Hospital mortality of
these patients has been reported to be 44 to 64%
[5,13,15-19]. Higher disease severity [3], use of vasoac-
tive drugs, mechanical ventilation, sepsis [1] and longer
hospital stay prior to ICU ad-mission [17] are associated
with increased hospital mortality. Surgical admission is
related with better outcome [17,19]. Furthermore,
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health-related quality of life (HRQoL) of RRT-treated
AKI patients has been reported to be lower than in gen-
eral population [20]. However, the number of patients
in these studies has been limited [6,20,21]. Studies pre-
senting the incidence of RRT-treated AKI in general
ICU patients along with long-term outcome and
HRQoL are scarce.
Accordingly, we aimed to evaluate the nationwide
incidence of RRT-treated AKI in Finland, and their hos-
pital and six-month mortality, and their HRQoL at base-
line and after six months follow-up.
Materials and methods
The board of the Finnish Intensive Care Consortium
(FICC) approved the study protocol. The Ethics Com-
mittee of the Department of Surgery, Hospital District
of Helsinki and Uusimaa waived the need for an
informed consent. The consortium maintains a database,
where detailed data on patient characteristics, disease
severity scores, and patient outcomes are prospectively
collected and validated. During the study period from 1
January 2007 to 31 December 2008, the database
included all admissions in nine ICUs of five Finnish
University hospitals and in 15 central hospitals and
included 30,380 ICU admissions. Four highly specialised
units were not members of the consortium, but the
number of RRT-treatments in these units is minimal.
Thus, all general ICUs providing RRT were included in
the study.
We searched the database for patients who had
received RRT due to AKI. RRT and the day of RRT
initia-tion were registered in the database. For compari-
son, we obtained the same data on all ICU patients for
the same period. For all analyses we excluded readmis-
sions, patients under the age of 15, patients with end-
stage renal disease (ESRD) requiring dialysis prior to
ICU admission based on chronic health evaluation, and
patients admitted because of drug or alcohol intoxi-
cation.
The data of each patient treated in the ICU during the
study period included 1) demographic data, 2) SAPS II
(Simplified Acute Physiology Score) [22] and SOFA
(Sequential Organ Failure Assessment) severity scores
and organ spe-cific SOFA scores [23], 3) intensity of
care measured by TISS (Therapeutic Intervention Scor-
ing System) score [24], 4) APACHE (Acute Physiology
and Chronic Health Evaluation) III and ICD-10 (Inter-
national Classification of Diseases, 10th revision) diagno-
sis and the APACHE III diagnosis group, 5)
physiological data, and 6) laboratory values. In addition
to daily creatinine values, we obtained the data of the
severity scores as well as physiological and laboratory
values from the first 24-hour ICU-treatment period. If
data were missing for more than 5% of cases, we
indicate it in the tables. We used the Finnish population
data from Statistics Finland for the epidemiological cal-
culations. On 31 December 2007, Finland (except the
Åland Islands) had 4,383,358 ≥ 15-year-old inhabitants.
We analysed the data on ICU and hospital length of
stay, hospital mortality and six-month mortality. We cal-
culated the standardised mortality ratio (SMR, the num-
ber of observed hospital deaths divided by the number
of expected deaths) according to the original SAPS II
equation [22].
We classified the patients according to the maximum
RIFLE class [4] during their ICU stay. Due to missing
urine output data we only used the glomerular filtration
rate (GFR) criteria: RIFLE-Risk serum creatinine ≥ base-
line creatinine × 1.5; RIFLE-Injury serum creatinine ≥
baseline × 2; RIFLE-Failure serum creatinine ≥ baseline
× 3 or > 354 micromol/l with an acute rise > 44 micro-
mol/l [4]. As baseline creatinine we used the lowest
value of the follow-ing: the lowest creatinine during the
patient’s ICU stay (in 76% of the cases) or calculated
creatinine from the MDRD (Mod-ification in Diet in
Renal Disease) equation [25] assuming a glomerular fil-
tration rate of 75 ml/minute/1.73 m2 as recom-mended
by ADQI (Acute Dialysis Quality Initiative) [4]. We
determined the day of RRT initiation and the preceding
RIFLE class.
We analysed the HRQoL with the EuroQol (EQ-5D)
instrument [26,27]. EQ-5D includes five dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension is scored from 1 to
3 and population-based preference weights are used to
calculate the index score (maximum value 1) (Additional
file 1). The instrument also includes a visual analogue
scale (VAS) ranging from 0 to 100 (100 represents the
best) for self-rating the health state. The baseline values
were obtained during the patients ICU stay by inter-
viewing either the patient himself or his proxy. For fol-
low-up, the query was performed by a phone interview
or a letter, depending on the practice in each centre.
We calculated the EQ-5D index score and analysed it
and the VAS score at baseline and after six months fol-
low-up among patients who were reported to be alive at
six months.
To compare septic and non-septic patients, we
searched the patients with infection diagnosis by screen-
ing the APACHE III and ICD-10 diagnoses. We
screened all patients for fulfilling the SIRS (systemic
inflammatory response syndrome) -criteria [28]. We
classified patients having sepsis if they had infection
diagnosis and fulfilled at least two SIRS criteria, severe
sepsis if they had sepsis and at least one non-cardiovas-
cular organ failure defined by organ specific SOFA score
3 or 4, and septic shock if they had sepsis and the cardi-
ovascular SOFA score was 3 or 4. We only included
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patients with emergency admission in the final analysis
regarding sepsis in order to enhance the aptness of the
retrospective sepsis classification.
We performed statistical analysis using SPSS Statistics
19.0 (SPSS Inc., Chicago, IL, USA). We report con-tinu-
ous data as medians with interquartile range (IQR, 25th
to 75th percentiles) and categorical data as percentages
and count. We calculated 95% confidence intervals (CI)
for the main outcome data. We used Mann-Whitney U-
test to compare continuous variables and Chi-square
test to compare categorical data. We compared repeated
measurements (EQ-5D and VAS scores) with the Wil-
coxon signed rank test. Reported P-values were two-
sided and significance was set at the 0.05 level.
We conducted a multiple logistic regression analysis
to assess independent risk factors for hospital mortality
of patients treated with RRT. We used a backwards
elimination approach and a significance level of < 0.05
for entry and > 0.10 for stepwise removal. We entered
the following variables: gender, admission type (surgical/
medical), time from hospital admission to ICU admis-
sion (days), SAPS II score, SOFA score and presence of
severe sepsis. In the first model we found SOFA score
not to be associated with mortality and, therefore, per-
formed the second model where we replaced SOFA
score with organ-specific variables: need for vasoactive
drugs, need for mechanical ventilation, and serum crea-
tinine. We tested the goodness of fit with the Hosmer-
Lemeshow C-statistics. We report odds ratios with 95%
CI.
Results
We analysed the final cohort of 24,904 patients admitted
to ICU from 1 January 2007 to 31 December 2008 (Fig-
ure 1). Of these patients, 1,686 received RRT due to
AKI. The incidence of RRT-treated AKI was 6.8% (95%
CI 6.5 to 7.1%) among ≥ 15-year-old general ICU
patients, which corresponds to a yearly population-
based incidence of 19.2 per 100,000 (95% CI 17.9 to
20.5) among ≥ 15 year old inhabitants in Finland.
Characteristics of the patients are presented in Table
1. No significant difference in the age between patients
treated with RRT (RRT patients) and patients who did
not require RRT (non-RRT patients) existed (P = 0.173).
The APACHE III diagnosis groups on admission are
presented in Table 2. We were able to classify 85.3% of
the cohort according to RIFLE GFR criteria. Patients
according to the maximum RIFLE class are presented in
Table 3. Of the whole cohort, 5,662 of 21,251 patients
(26.6%; 95% CI 26.0 to 27.2%) had AKI according to
RIFLE (R-F), and of these AKI patients, 1,120 (19.8%)
received RRT. Of all patients with AKI, 66.3%, 79.2%
and 90.1% reached their maximum RIFLE-class during
the first two, three and five days of ICU treatment,
respectively. We identified 1,752 patients with RIFLE-F
of whom 776 (44.3%) received RRT. RRT was initiated
within the first day in the ICU in 66.4% of the RRT
patients. By days 2, 3 and 5 RRT was initiated for 83.3%,
90.1% and 95.1% of the RRT patients.
Outcome data and data on HRQoL as measured with
the EQ-5D index and VAS scores are presented in
Table 4, and the responses of the EQ-5D questionnaire
at six months in Additional file 1. Hospital mortality of
RRT patients stratified according to the timing of RRT
initiation was 33.1% in patients with early (days 1 to 2)
RRT, 39.8% with delayed (days 3 to 5) RRT, and 53.5%
with late (from day 6 onwards) RRT (P < 0.001).
In multiple logistic regression analysis the time from
hospital admission to ICU admission (days) and SAPS II
score on admission (one point increments) were inde-
pendently associated with increased risk for hospital
mortality of RRT patients. The odds ratios (95% CI)
were 1.055 (1.029 to 1.081) (P < 0.001) per one day and
1.056 (1.048 to 1.065) (P < 0.001) per one SAPS II
point, respectively. Higher serum creatinine and absence
of severe sepsis were associated with a decreased risk
for hospital death with odds ratios (95% CI) of 0.998
(0.997 to 0.999) per each micromol/l (P < 0.001) and
0.682 (0.528 to 0.881) (P = 0.003), respectively. The
Hosmer-Lemeshow C-statistics for the final model was
5.771 (P = 0.673).
Of the 1,553 RRT patients with emergency admission,
503 (32.4%) had severe sepsis. Characteristics and out-
come data of RRT patients with and without severe sep-
sis are presented in Additional file 2. Hospital mortality
in RRT patients with severe sepsis was 44.5% (40.2 to
48.8%), and in non-RRT patients with sepsis or severe
sepsis 19.3% (18.0 to 20.6%) (P < 0.001).
Discussion
This large, retrospective multi-centre cohort study
included all Finnish adult general ICU patients in a per-
iod of two years. We found that the population-based
incidence of AKI treated with RRT was 19.2 per 100,000
among ≥ 15-year-old inhabitants in Finland. During the
study period, 6.8% of patients admitted to general ICUs
were treated with RRT and 26.6% had AKI according to
RIFLE classification. Hospital mortality of RRT patients
was significantly higher compared to non-RRT patients,
35.0% vs. 15.5%.
The previously reported population-based incidence of
RRT-treated AKI varies from 8 to 30 per 100,000 [5-12].
In the nationwide prospective Australian study by Silve-
ster et al. [5] the incidence of AKI treated with RRT in
an ICU setting was 8 per 100,000. Furthermore, RRT
incidence in the United States in a study based on diag-
nosis and procedure codes in the Nationwide Inpatient
Sample registry was 27 per 100,000 [11]. The study also
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included patients with chronic kidney disease (CKD)
[11]. Incidence of RRT-treated AKI was 28.6 per
100,000 in a prospective Scottish study conducted both
in ICU and dialysis unit settings [10]. The population-
based incidence of RRT in our study was 19.2 per
100,000, in broad agreement with the previous reports.
In Finland, RRT administered due to AKI outside ICUs
is rare, and, thus, lack of these data may have caused
only a minor bias in the population-based incidence.
The proportion of RRT-treated AKI in our study was in
line with previous recent reports from other countries
[1,3,13,14].
The incidence of AKI defined by RIFLE has been
reported to vary between 11 and 67% among ICU
patients [2,3,29]. In the study by Joannidis et al. [29],
the incidence of AKI defined by the GFR criteria alone
was lower, 25% compared to 35%, when urine output
criteria also were considered. Since we were able to clas-
sify patients only on the basis of RIFLE GFR criteria, the
proportion of AKI patients may be slightly
30,380 patients admitted to ICU 
Exclusions 
-2,103 readmissions 
-599 <15 years old 
-589 patients with ESRD 
-2,185 intoxications 
24,904 patients analysed 
- 4,193 / 24,887 (16.8%) died                        
in the hospital 
1,686 RRT patients 
-589 / 1,685 (35.0%) died 
503 RRT patients with 
emergency admission and 
severe sepsis / septic shock  
-224 / 503 (44.5%) died 
23,218 non-RRT patients 
-3,604 / 23,202 (15.5%) died 
3,658 non-RRT patients with 
emergency admission and sepsis / 
severe sepsis / septic shock  
- 706 / 3,658 (19.3%) died 
Figure 1 Flow chart of the patient inclusion and grouping and the hospital mortality in each group. Mortality is expressed as no./total
no (%). ICU, intensive care unit; ESRD, end-stage renal disease; RRT, renal replacement therapy; non-RRT patients, patients who did not need
renal replacement therapy.
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underestimated, and may explain along with the early
initiation of RRT why 16% of the RRT patients did not
fill the RIFLE GFR criteria. Interestingly, the mortality
of RIFLE-F patients with or without RRT did not differ,
and RRT patients with RIFLE-I or RIFLE-R had higher
mortality rates than RIFLE-F RRT patients. With urine
output criteria these RIFLE-R and RIFLE-I patients
might have reached RIFLE-F class. Previously, it has
been reported that 14 to 30% of RIFLE-F patients had
received RRT [2,3]. In our study, the proportion was
greater, although the overall population-based incidence
of RRT corresponded with previous studies.
In this study, the hospital mortality of RRT patients
with corresponding characteristics and disease severity
(SAPS II has ranged from 45 to 48 in studies with
reported values [13,17,18]) was lower than in previous
studies with mortality rates between 44 and 64%
[13,15-19]. The lowest hospital mortality rates have
been from 44 [15] to 47% [5]. In both studies half of
the patients had severe sepsis [5,15]. Silvester et al. [5]
reported a mean SAPS II score of 55, which equals the
score of the RRT patients with severe sepsis in our
study, whose hospital mortality was 44.5%. Waikar et
al. [11] reported hospital mortality of RRT-treated
patients to be only 28.1%, but the study included also
patients with CKD. A third of RRT patients in our
study had severe sepsis compared to half in previous
studies with higher hospital mortality rates [16-18]. A
smaller proportion of patients with severe sepsis may
have contributed to the lower mortality rate in our
study. However, RRT patients with severe sepsis had a
lower mortality rate compared to previous reports
[16-18]. Hospital mortality of septic AKI patients (of
whom 70% received RRT) with corresponding severity
of disease has been reported to be 70% [30]. In our
cohort, RRT was initiated earlier compared to the
study by Bagshaw et al. [31]. Tendency to initiate RRT
early in Finland offers one possible explanation for bet-
ter survival. Delannoy et al. [21] reported the six-
month mortality of RRT-treated AKI patients with
median SAPS II score of 63 to be 62%. In our study,
the most severely ill patients (RRT patients with severe






Age - median (IQR) (yr) 63 (52 to 72) 62 (50 to 73) 0.173
Male gender - no./total no. (%) 1,143/1,685 (67.8%) 14,641/23,200 (63.1%) < 0.001
SAPS II score - median (IQR) 48 (37 to 62) 33 (23 to 46) < 0.001
SOFA (1.d) score - median (IQR) 10 (7 to 13) 6 (3 to 8) < 0.001
Mean daily TISS score - median (IQR) 36.4 (29.7 to 43.2) 28.7 (22.4 to 35.0) < 0.001
Emergency admission - no./total no. (%) 1,558/1,684 (92.5%) 19,122/23,202 (82.4%) < 0.001
Surgical admission- no./total no. (%) 410/1,685 (24.3%) 9,426/23,208 (40.6%) < 0.001
Sepsis/severe sepsis - no./total no.(%) 510/1,681 (30.3%) 3,753/23,101 (16.2%) < 0.001
Mechanical ventilation - no./total no. (%) 1,014/1,642 (61.8%) 11,116/22,409 (49.6%) < 0.001
Vasoactives-no./total no. (%) 1,067/1,671 (63.9%) 9,556/23,175 (41.2%) < 0.001
Creatinine - median (IQR) (micromol/L) 210 (119 to 352)* 72 (56 to 101)† < 0.001
Urine output - median (IQR) (mL/d) 829 (232 to 1,947) 2,355 (1,555 to 3,390) < 0.001
IQR, Interquartile range (25th to 75th percentiles); SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TISS, Therapeutic
Intervention Scoring System. * Data missing for 5% of cases. †Data missing for 7% of cases.
Table 2 The APACHE (Acute Physiology and Chronic
Health Evaluation) III diagnostic groups of the patients
RRT Non-RRT
Total no. of patients* 1,685 23,208
Non-operative 1,275 (75.7%) 13,782 (59.4%)
Cardiovascular 153 (9.1%) 3,111 (13.4%)
Gastrointestinal 149 (8.8%) 1,338 (5.8%)
Hematological 22 (1.3%) 65 (0.3%)
Metabolic 102 (6.1%) 891 (3.8%)
Neurological 74 (4.4%) 2,423 (10.4%)
Renal 257 (15.3%) 159 (0.7%)
Respiratory 146 (8.7%) 2,572 (11.1%)
Sepsis 284 (16.9%) 1,110 (4.8%)
Trauma 25 (1.5%) 1,115 (4.8%)
Other 44 (2.6%) 661(2.8%)
Missing 19 (1.1%) 337 (1.5%)
Postoperative 410 (24.3%) 9,426 (40.6%)
Cardiovascular 177 (10.5%) 2,947 (12.7%)
Gastrointestinal 137 (8.1%) 2,290 (9.9%)
Gynecological 8 (0.5%) 313 (1.3%)
Neurological 29 (1.7%) 2,060 (8.9%)
Orthopedic 7 (0.4%) 391 (1.7%)
Renal 12 (0.7%) 224 (1.0%)
Respiratory 13 (0.8%) 563 (2.4%)
Trauma 11 (0.7%) 419 (1.8%)
Missing 16 (0.9%) 219 (0.9%)
RRT; renal replacement therapy, non-RRT; patients without renal replacement
therapy * Data on APACHE III diagnosis group were missing for one RRT
patient and 10 non-RRT patients.
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sepsis) had slightly lower SAPS II scores and a six-
month mortality rate of 59%.
The SAPS II based SMR of RRT patients was 0.76 in
our study. Previously, Uchino et al. [17] have reported a
SMR of 1.38 among patients receiving continuous RRT.
Silvester et al. [5] reported a SAPS II predicted mortality
of 51.2% with an observed mortality of 46.8% and in the
study by Metnitz et al. [13] the SAPS II predicted and
observed mortality were 44.7% and 62.8%, respectively.
The SMRs yielded from both of these studies remain
higher than in our study. It has been discussed that
SAPS II may underestimate the mortality of patients
with AKI [1], while our results imply that SAPS II gen-
erally overestimates the mortality of both RRT and non-
RRT patients. Given the lower SMR of RRT patients
compared to non-RRT patients, the treatment of RRT
patients may not have improved as much as the treat-
ment of non-RRT patients since the validation of SAPS
II scoring system.
As we found in the multiple regression analysis, longer
time from hospital admission to ICU among patients
receiving continuous RRT [17] and high SAPS II score
among AKI patients have been associated with increased
mortality, while the absence of severe sepsis has been
associated with better survival [1]. We found an associa-
tion with higher creati-nine on ICU admission and
decreased risk for mortality, potentially reflecting that
patients with higher creatinine had more often isolated
AKI. Higher creatinine on the day of RRT initiation has
been associated with decreased mortality [31,32], which
may be explained by better nutritional status reflecting
better overall health status [31,32] or underlying CKD
and an acute-on-chronic kidney injury with different
prognosis [31]. Lower creatinine and worse outcome
may account for volume overload known to be indepen-
dently associated with increased mortality [31,32].
We were able to obtain the six-month follow-up EQ-
5D index score only from 44% of RRT patients, which
may have caused bias. Our cohort of 313 patients, how-
ever, is the second largest to our knowledge of RRT-
treated patients with HRQoL data. In addition, we com-
pared the HRQoL of RRT patients to non-RRT patients.
Table 3 Patients classified according to RIFLE (Risk, Injury, Failure) glomerular filtration rate criteria
All (N = 24,904) RRT (N = 1,686) RRT, before* Non-RRT (N = 23,218)
No AKI 15,589 (73.4%) 219 (16.4%) 147 (19.8%) 15,370 (77.2%)
Risk 2,198 (10.3%) 100 (7.5%) 62 (8.4%) 2,098 (10.5%)
Injury 1,712 (8.1%) 244 (18.2%) 150 (20.2%) 1,468 (7.4%)
Failure 1,752 (8.2%) 776 (58.0%) 383 (51.6%) 976 (4.9%)
No data 3,653 (14.7%) 347 (20.6%) 944 (56%) 3,306 (14.2%)
AKI, Acute kidney injury; RRT; renal replacement therapy, non-RRT; patients without renal replacement therapy *RIFLE class before the initiation of RRT






ICU stay - median (IQR) days 5.2 (1.9 to 10.8) 1.5 (0.9 to 3.2) < 0.001
Hospital stay - median (IQR) days 16 (8 to 29) 9 (5 to 16) < 0.001
Treatment restricted -no./total no. (%) 388/1,533 (25.3%) 2,665/21,339 (12.5%) < 0.001
Hospital mortality -no./total no. (% (95%CI)) 589/1,685 (35.0% (32.7 to 37.3%)) 3,604/23,202 (15.5% (15.0 to 16.0%)) < 0.001
Hospital mortality -No AKI according to RIFLE -no./total no. (%) 40/219 (18.3%) 1,573/15,364 (10.2%) < 0.001
Hospital mortality -RIFLE -Risk -no./total no. (%) 40/100 (40%) 480/2,095 (22.9%) < 0.001
Hospital mortality -RIFLE -Injury -no./total no. (%) 128/244 (52.5%) 430/1,468 (29.3%) < 0.001
Hospital mortality -RIFLE -Failure -no./total no. (%) 245/776 (31.6%) 326/976 (33.4%) 0.417
SAPS II based SMR - (95% CI) 0.76 (0.70 to 0.82) 0.61 (0.59 to 0.63)
Six-month mortality -no./total no. (% (95%CI)) 699/1,415 (49.4% (46.8 to 52.0%)) 5,101/18,367 (27.8% (27.2 to 28.5%)) < 0.001
EQ-5D index at baseline - median (IQR) - no./total no. (%) 0.68 (0.49 to 1.0) 431/716 (60.2%) 0.69 (0.53 to 1.0) 7,487/13,266 (56.4%) 0.004
EQ-5D index at six months - median (IQR) - no./total no. (%) 0.63 (0.49 to 0.79)
313/716 (43.7%)
0.68 (0.52 to 1.0)
5,415/13,266 (40.8%)
0.015
VAS at baseline - median (IQR) - no./total no. (%) 60 (40 to 80)
223/716 (31.1%)
70 (50 to 80)
4,505/13,266 (34.0%)
0.009
VAS at six months - median (IQR) - no./total no. (%) 70 (50 to 80)
274/716 (38.3%)
70 (55 to 85) 4,841/13,266 (36.5%) 0.059
Quality of life is measured with the EuroQol (EQ-5D) index and with the visual analogue scale (VAS) score. AKI; Acute kidney injury, IQR; interquartile range (25th
to 75th percentiles), RIFLE, Risk, Injury, Failure -classification; SAPS, Simplified Acute Physiology Score; SMR, standardised mortality ratio. Treatment restrictions
include: 1) no resuscitation, 2) no increase in the intensity of treatment, 3) treatment withdrawal.
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Among cancer patients, 0.06 to 0.08 has been consid-
ered as a minimally important clinical difference in the
EQ-5D index score and 7 for the VAS score [33]. Sev-
eral previous studies have reported lower HRQoL
among RRT patients compared to matched general
population [20,21]. Morsch et al. [34] found that
younger and less severely ill RRT-treated patients had
better HRQoL as measured with the SF-36 instrument
than older patients with long hospital stay. Johansen et
al. [35] reported an extremely low HRQoL among 60-
day survivors after RRT. We found no clinically signifi-
cant difference in EQ-5D score between RRT and non-
RRT patients after six months follow-up. Regarding the
five dimensions of the EQ-5D index, the groups did not
differ in suffering from pain or anxiety, and differences
in scores for mobility, self-care and usual activities were
small. In addition, the VAS score reflecting the patients
own perception of health at six months of RRT patients
corresponded with the score of non-RRT patients and
the earlier reported score of general population [20].
There are some limitations to our study. First, the
data were prospectively collected as a routine set of all
ICU admissions and, therefore, not addressed to answer
specific questions regarding the received RRT. Accord-
ingly, we lack information on the modality and dose of
RRT. Second, we were unable to apply the urine output
criteria of RIFLE classifica-tion and obtain a true base-
line creatinine. Third, the six-month mortality rate was
available only from 80% of the patients. However, our
cohort is to the best of our knowledge the largest popu-
lation reporting six-month mortality data of RRT-treated
AKI among critically ill patients.
Conclusions
In conclusion, the population-based incidence of AKI
treated with RRT was 19.2 per 100,000. Of all ICU
patients, 6.8% received RRT and 26.6% had AKI accord-
ing to RIFLE classification. In this unselected population
of general ICU patients, the hospital and six-month
mortality rates were lower than previously reported for
ICU-treated RRT patients.
Key messages
• Population-based incidence of RRT-treated AKI
was 19.2 per 100,000 in Finland and 6.8% of all
adult general ICU-patients.
• Hospital and six-month mortality of patients trea-
ted with RRT were 35.0% and 49.4%, respec-tively.
• Patients treated with RRT perceived their health
related quality of life after six-months follow-up as
good as patients treated without RRT and general
population.
Additional material
Additional file 1: EQ-5D health-related quality of life in critically ill
patients with renal replacement therapy (RRT) at six months.
Additional file 2: Characteristics and outcome of critically ill
emergency patients treated with renal re-placement therapy
according to presence or absence of severe sepsis or septic shock.
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